Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-954 PK in Renal Impairment
NCT03296787Phase 1Completed
- Sponsor
- Takeda
- Start
- Nov 2017
- Primary completion
- Aug 2019
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of felcisetrag in enteral feeding intolerance (EFI) and Postoperative gastrointestinal dysfunction (POGD) (5 arms), sponsored by Takeda. Primary endpoints: Maximum Observed Plasma Concentration, Area Under the Plasma Concentration-time Curve From Time 0 to 72 Hours and 6 more. Started Nov 2017; status: completed.
02
Drugs
felcisetrag
03
Conditions
enteral feeding intolerance (EFI)Postoperative gastrointestinal dysfunction (POGD)
Beyond the preview
Go deeper on NCT03296787.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03296787.